Redhawk Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Redhawk Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,288	Closed	-$237K	–	306
2021 Q2	$237K	Buy	+1,288	New	+$221K	0.05%	213
2019 Q3	–	Sell	-225	Closed	-$29K	–	494
2019 Q2	$29K	Buy	+225	New	+$29K	0.01%	298

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Redhawk Wealth Advisors's ALXN Position: Q3 2021 in Review

Redhawk Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,288 shares — an estimated $237K sold.

Redhawk Wealth Advisors first reported a position in ALXN in Q2 2019 and held it in 2 quarters. The position peaked at $237K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Redhawk Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Redhawk Wealth Advisors sold 1,288 Alexion Pharmaceuticals shares in Q3 2021, an estimated $237K.
Redhawk Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 2 quarters.
Redhawk Wealth Advisors's Alexion Pharmaceuticals position peaked at $237K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Redhawk Wealth Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.